Episode 201: Dr. Audrey Cook on Advances in Diabetes Treatment and Therapeutic Approaches

Michelle Meyer, DVM and Audrey Cook, BVM&S, MRCVS, MSc Vet Ed, DACVIM (SAIM), DECVIM-CA, DABVP (Feline) join us in this episode to detail the massive shift and advances that have been made in feline diabetes treatment with the introduction of the new drug class of SLGT2 inhibitors, velagliflozin (Senvelgo®) and bexagliflozin (Bexacat™). While a standard of care in human diabetes treatment for over a decade, these drugs received recent FDA approval for use in feline patients. Over the course of the conversation, Dr. Cook reviews which patients are best suited for the new therapeutics; what equipment your practice should utilize to conduct diagnostic tests to determine your treatment approach; and the side effects to be cognizant of and educate caregivers. Dr. Cook also touches upon what to do with hypoglycemia instances, if cats with comorbidities can utilize these therapeutics, and the life-changing effects these drugs will have on the lives of caregivers.

For more in-depth information, be sure to check out Dr. Audrey Cook’s sessions on-demand from the 2023 Annual Conference at www.catvets.com/2023conference.

Thank you to our sponsor Boehringer-Ingelheim for supporting this episode!